Metagenomi Therapeutics (MGX) Capital Expenditures (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Capital Expenditures of $25000.0 for Q1 2026, down 91.32% year-over-year from $288000.0 in Q1 2025, and down 95.02% quarter-over-quarter from $502000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Capital Expenditures (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Capital Expenditures data on file, last reported at $25000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $25000.0, down 91.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $311000.0 (down 87.49% YoY), and the FY2025 annual result was $574000.0, down 81.57% from the prior year.
- Capital Expenditures eased to $25000.0 in Q1 2026 per MGX's latest filing, from $502000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $6.5 million in Q3 2023 and troughed at -$1.1 million in Q2 2023.
- A 4-year average of $1.0 million and a median of $288000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures surged 116.09% in 2024, then tumbled 242.77% in 2025.
- A 4-year view of Capital Expenditures shows it stood at $1.7 million in 2023, then surged by 63.67% to $2.8 million in 2024, then plunged by 82.34% to $502000.0 in 2025, then plunged by 95.02% to $25000.0 in 2026.
- Business Quant data shows MGX's Capital Expenditures at $25000.0 in Q1 2026, $502000.0 in Q4 2025, and $31000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -63,220.27 |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | 25,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25,000.00 |
| Mar 31, 2026 | 25,000.00 |
| Dec 31, 2025 | 502,000.00 |
| Dec 31, 2025 | 502,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | -247,000.00 |
| Jun 30, 2025 | -247,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | 2.84 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | -817,000.00 |
| Sep 30, 2024 | -817,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 915,000.00 |
| Mar 31, 2024 | 915,000.00 |
| Dec 31, 2023 | 1.74 Mn |
| Dec 31, 2023 | 1.74 Mn |